Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 7/20 | 0.35 |
| ▸ | CA2 | P00918 | 7/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31306077 | 1.00 | CAPN1 (0.35) | CAPN1CA1CA2GRIA2KEAP1 | |
| SCHEMBL20269098 | 1.00 | CAPN1 (0.35) | CAPN1CA1CA2GRIA2KEAP1 | |
| SCHEMBL30620251 | 1.00 | CAPN1 (0.35) | CAPN1CA1CA2GRIA2KEAP1 | |
| SCHEMBL18733699 | 1.00 | CAPN1 (0.35) | CAPN1CA1CA2GRIA2KEAP1 | |
| SCHEMBL20284973 | 0.85 | PSEN1 (0.35) | CAPN1CA1CA2GRIA2KEAP1 | |
| SCHEMBL16852800 | 0.85 | GRIA2 (0.36) | CA1CA2GRIA2KEAP1MTNR1A | |
| SCHEMBL20272821 | 0.80 | CA1 (0.49) | CA1CA2 | |
| SCHEMBL20269934 | 0.80 | CA1 (0.49) | CA1CA2 | |
| SCHEMBL21631288 | 0.80 | CA1 (0.49) | CA1CA2 | |
| SCHEMBL16831955 | 0.79 | CA1 (0.41) | CAPN1CA1CA2GRIA2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084077-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| US-12091409-B2 | Ether linked triazoles as NRF2 activators | ASTEX THERAPEUTICS LIMITED (GB) | 2024-09-17 | — | — | US | disclosed |
| US-20220089590-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2022-03-24 | — | — | US | disclosed |
| EP-3555082-B1 | ETHER LINKED TRIAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-26 | — | — | EP | disclosed |
| EP-3555082-B1 | ETHER LINKED TRIAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-11059816-B2 | Ether linked triazoles as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-13 | — | — | US | disclosed |
| US-11059816-B2 | Ether linked triazoles as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-13 | — | — | US | disclosed |
| US-20200071317-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| US-20200071317-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| US-20200071310-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| US-20200071310-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2018109649-A1 | ETHER LINKED TRIAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059816-B2 | Ether linked triazoles as NRF2 activators | NFE2L2, KEAP1, NQO1 | CAPN1 3552/4885CA1 4834/4885CA2 4168/4885 |
| US-20220089590-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | CAPN1 3552/4885CA1 4834/4885CA2 4168/4885 |
| US-20250084077-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | CAPN1 3552/4885CA1 4834/4885CA2 4168/4885 |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | NFE2L2, KEAP1, NQO1 | CAPN1 3452/4885CA1 4877/4885CA2 4534/4885 |
| US-12091409-B2 | Ether linked triazoles as NRF2 activators | NFE2L2, KEAP1, NQO1 | CAPN1 3552/4885CA1 4834/4885CA2 4168/4885 |
| US-20200071317-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | CAPN1 3552/4885CA1 4834/4885CA2 4168/4885 |
| US-20200071310-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, NQO1, KEAP1 | CAPN1 3084/4885CA1 4883/4885CA2 4718/4885 |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | CAPN1 3452/4885CA1 4877/4885CA2 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.